Evaluation of 0.25% AGN-229666 ophthalmic solution compared to vehicle or olopatadine in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2017
At a glance
- Drugs AGN 229666 (Primary) ; Olopatadine
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 06 Sep 2017 Last checked against University Hospital Medical Information Network - Japan record.
- 05 Sep 2017 Status changed from not yet recruiting to recruiting.
- 17 Aug 2017 New trial record